Clinical trials: FLU
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A H3N2, Influenza A H1N1
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Influenza, or the flu, is an infectious respiratory disease that can range in severity from mild to severe to even death. This study aims to evaluate a treatment for people who are hospitalized with the flu.
- Trial name
- NCT03315104
- Testing
- FLU-IGIV
- Where
- 55 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- Emergent BioSolutions
Influenza Prophylaxis
Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
The primary objective of this study was to evaluate if administration of a seasonal flu vaccine using a jet injector device is comparable to traditional needle and syringe delivery for eliciting an immune response.
- Trial name
- NCT01644149
- Testing
- Stratis Jet Injector, Needle and Syringe, 2011-2012 Fluzone trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- PharmaJet, Inc.
Human Influenza
Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
To evaluate the safety of a single intramuscular (IM) injection of trivalent adjuvanted influenza study vaccine, formulation 2012/2013, in elderly subjects and the antibody response to each influenza vaccine antigen, as measured…
- Trial name
- NCT01651104
- Testing
- Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: To describe the immunogenicity of the candidate vaccines after a single injection.
- Trial name
- NCT00952276
- Testing
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Where
- 15 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Human
A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A)…
- Trial name
- NCT05823974
- Testing
- F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z
- Where
- 41 sites in United States, Belgium and 2 more
- Volunteers
- 1,275 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V
The study aims to evaluate the immunogenicity of a single full (0.5 mL) dose and a 0.25 mL 2-dose regime of Inflexal V in unprimed children aged 6 - <36 months, using the EMA guideline for the re-registration of the seasonal…
- Trial name
- NCT01229397
- Testing
- Inflexal V
- Where
- 2 sites in Italy
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Cytomegalovirus Infections, Influenza
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
In this study we are trying to understand whether previous infection with a particular virus, namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new infections or vaccinations with age.
- Trial name
- SLVP025 (NCT02134184)
- Testing
- Fluzone® 2012-2013 Formula NDC No 498281-012-50
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Stanford University
Seasonal Influenza
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
- Trial name
- IGNITE P303 (NCT05827978)
- Testing
- mRNA-1010, Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
- Where
- 103 sites in United States
- Volunteers
- 8,411 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Influenza Immunisation
Age and Response to Flu Vaccines
The study will be designed as a prospective surveillance of the immune response to seasonal influenza vaccination in 240 healthy children and adults ages 9 and over.
- Trial name
- NCT03328325
- Testing
- Influenza Virus Quadrivalent Inactivated Vaccine
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Respiratory Infection
Study on Safety and Effectiveness of Ergoferon in the Treatment of Flu / ARVI in Outpatients.
The observational study to get the additional data of the safety and effectiveness of Ergoferon in the treatment of influenza/ARVI in adult and pediatric outpatients.
- Trial name
- HERMITAGE (NCT04413929)
- Testing
- Ergoferon
- Volunteers
- 8,411 people
- Sponsor
- Materia Medica Holding
Influenza
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older
The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co.
- Trial name
- NCT02218697
- Testing
- Influsplit™ Tetra (Fluarix™ Tetra), Pneumovax™ 23
- Where
- 6 sites in Belgium, France
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV
The objective of this pilot study is to assess the immunogenicity and reactogenicity of Fluzone High Dose with Fluzone (standard adult dose) influenza vaccines in healthcare workers.
- Trial name
- NCT02263040
- Testing
- Fluzone High-Dose, Fluzone (standard dose)
- Where
- Canada
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Influenza Infection
Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants
The purpose of this study is to evaluate the immunogenicity and safety of TAK-850 administered subcutaneously as a single dose versus influenza HA vaccination in an exploratory manner.
- Trial name
- NCT02555618
- Testing
- TAK-850, Influenza HA vaccine
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
The aim of the trial is to evaluate immunogenicity and safety of the quadrivalent influenza vaccine (QIV) and the trivalent influenza vaccine (TIV) (split-virion inactivated) Northern Hemisphere (NH) 2015 2016 seasonal…
- Trial name
- NCT02550197
- Testing
- Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016, Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
- Where
- 5 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older
The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese…
- Trial name
- NCT01114620
- Testing
- Arepanrix™
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Respiratory Viral Infections, Influenza
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
A multicenter double-blinded, randomized, placebo-controlled, parallel-group comparative Phase II clinical study to assess safety, tolerability, efficacy and optimal dose of XC221 vs.
- Trial name
- NCT03455491
- Testing
- XC221 100 mg, XC221 200 mg
- Where
- 11 sites in Russia
- Volunteers
- 120 people
- Sponsor
- PHARMENTERPRISES LLC
Influenza, Orthomyxoviridae Infections
Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®
Primary Objective: To provide the Center for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2008-2009 formulation of the inactivated, split-virion influenza vaccine Fluzone® for…
- Trial name
- NCT00755274
- Testing
- Influenza Virus Vaccine No Preservative: Pediatric Dose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants
Severe influenza respiratory disease is increasingly recognized in children. Influenza hospitalization rates in high-risk infants, such as premature infants, are increased some five-fold over rates in other children.
- Trial name
- NCT01194297
- Testing
- Live attenuated influenza vaccine, Inactivated influenza vaccine
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Rochester